These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19516028)

  • 21. Doctors and drug companies.
    Blumenthal D
    N Engl J Med; 2004 Oct; 351(18):1885-90. PubMed ID: 15509823
    [No Abstract]   [Full Text] [Related]  

  • 22. The Sunshine Act: how to avoid getting burned.
    Hurd P
    Fam Pract Manag; 2013; 20(5):8-10. PubMed ID: 24134101
    [No Abstract]   [Full Text] [Related]  

  • 23. Physician-vendor marketing and financial relationships under attack.
    Washlick JR; Welch SS
    J Health Life Sci Law; 2008 Oct; 2(1):151, 153-228. PubMed ID: 19004300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physician-industry relations--will fewer gifts make a difference?
    Steinbrook R
    N Engl J Med; 2009 Feb; 360(6):557-9. PubMed ID: 19196671
    [No Abstract]   [Full Text] [Related]  

  • 25. Physician payments sunshine act is now final.
    Schulte DJ
    Mich Med; 2013; 112(3):4. PubMed ID: 23914710
    [No Abstract]   [Full Text] [Related]  

  • 26. Should a medical practice accept a gift with strings attached?
    Agrawal M; Steinberg D
    Med Ethics (Burlingt Mass); 2001; ():3, 7. PubMed ID: 15584189
    [No Abstract]   [Full Text] [Related]  

  • 27. The death of common sense.
    Trachtman H
    Am J Bioeth; 2003; 3(3):W31-W32. PubMed ID: 14594484
    [No Abstract]   [Full Text] [Related]  

  • 28. German doctors free to take cash from drug firms.
    Hyde R
    Lancet; 2012 Aug; 380(9841):551. PubMed ID: 22891373
    [No Abstract]   [Full Text] [Related]  

  • 29. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry--self-regulation in the shadow of federal prosecution.
    Studdert DM; Mello MM; Brennan TA
    N Engl J Med; 2004 Oct; 351(18):1891-900. PubMed ID: 15509824
    [No Abstract]   [Full Text] [Related]  

  • 30. The physician and the pharmaceutical industry: both must keep the patient's interests at heart.
    Ravindran GD
    Issues Med Ethics; 1999; 7(1):21-2. PubMed ID: 16320467
    [No Abstract]   [Full Text] [Related]  

  • 31. Medical students protest perks from drug companies.
    Opar A
    Nat Med; 2006 Oct; 12(10):1104. PubMed ID: 17024192
    [No Abstract]   [Full Text] [Related]  

  • 32. A national survey of physician-industry relationships.
    Sade RM
    N Engl J Med; 2007 Aug; 357(5):507; author reply 508. PubMed ID: 17671263
    [No Abstract]   [Full Text] [Related]  

  • 33. Sunshine Act update.
    W V Med J; 2013; 109(5):40. PubMed ID: 24294711
    [No Abstract]   [Full Text] [Related]  

  • 34. Resident and fellow section. Conflicts of interest between physicians and the pharmaceutical industry: focus on headache medicine.
    Rubin EB; Bernat JL
    Headache; 2008; 48(10):1545-9. PubMed ID: 19076654
    [No Abstract]   [Full Text] [Related]  

  • 35. US campaign aims to end industry gifts, speaking fees, and travel for doctors.
    Tanne JH
    BMJ; 2007 Feb; 334(7590):385. PubMed ID: 17322228
    [No Abstract]   [Full Text] [Related]  

  • 36. Who rules the great Indian drug bazaar?
    Roy N
    Indian J Med Ethics; 2004; 1(1):2-3. PubMed ID: 16370060
    [No Abstract]   [Full Text] [Related]  

  • 37. Industry-to-physician marketing and the cost of prescription drugs.
    Chiong W
    Am J Bioeth; 2003; 3(3):W28-W29. PubMed ID: 14594480
    [No Abstract]   [Full Text] [Related]  

  • 38. Consultation starts on how to reveal payments from industry to doctors.
    Hawkes N
    BMJ; 2013 Jan; 346():f615. PubMed ID: 23360723
    [No Abstract]   [Full Text] [Related]  

  • 39. Take this medicine: the legality of prescription incentive schemes.
    Fanning J; Glover-Thomas N
    Med Law Rev; 2010; 18(3):417-26. PubMed ID: 20739438
    [No Abstract]   [Full Text] [Related]  

  • 40. Balancing innovation, access, and profits--market exclusivity for biologics.
    Engelberg AB; Kesselheim AS; Avorn J
    N Engl J Med; 2009 Nov; 361(20):1917-9. PubMed ID: 19828525
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.